Goserelin for Advanced Breast Cancer in Premenopausal Women
Author Information
Author(s): A.R. Dixon, J.F.R. Robertson, L. Jackson, R.I. Nicholson, K.J. Walker, R.W. Blamey
Primary Institution: City Hospital, Nottingham and Tenovus Institute for Cancer Research, University of Wales College of Medicine
Hypothesis
Can goserelin effectively treat premenopausal women with advanced breast cancer?
Conclusion
Goserelin treatment resulted in a 33% objective response rate with a median duration of response exceeding 15 months.
Supporting Evidence
- 25 patients (33%) showed an objective response to goserelin treatment.
- 7 patients (9%) had a complete response with a median duration of over 37 months.
- Response to therapy was significantly correlated with the oestrogen receptor status of the primary tumour.
Takeaway
Goserelin is a medicine that helps some women with advanced breast cancer feel better for a long time without needing surgery.
Methodology
75 premenopausal patients with advanced breast cancer were treated with monthly goserelin injections and assessed for response.
Limitations
53% of patients experienced disease progression while on goserelin.
Participant Demographics
Median age of participants was 44 years, with a range of 31-55 years.
Statistical Information
P-Value
0.009
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website